Evofem Biosciences, Inc., (NASDAQ: EVFM) saw its shares gain ground Wednesday on word it has entered into a new agreement with VitaCare Prescription Services, a wholly-owned subsidiary of GoodRx, to provide enhanced "white glove" support services to women prescribed Phexxi® (lactic acid, citric acid, potassium bitartrate) who choose to use Vita Care. Women or their health care provider can choose to have a Phexxi prescription sent to VitaCare for fulfillment, and VitaCare will help the patient understand coverage, identify available savings opportunities, and facilitate communication between the health care provider and payor.
"This new agreement with VitaCare significantly streamlines access to Phexxi, which we anticipate will lead to more patients filling their Phexxi prescriptions," said Chief Commercial Officer Katherine Atkinson.
Evofem's agreement with VitaCare also supports the Phexxi sales force through VitaCare's expertise in managing any prior authorizations and other obstacles to a woman filling her Phexxi prescription.
Evofem's agreement with VitaCare also supports the Phexxi sales force through VitaCare's expertise in managing any prior authorizations and other obstacles to a woman filling her Phexxi prescription.
Patients whose prescriptions go through VitaCare will have access to the following services:
Improved follow through on patient contact once the patient receives their Phexxi prescription; Personalized benefits guidance for patients; Support for prescribers and their patients with the prior authorization policies of health insurers and pharmacy benefit managers; Pharmacy transfers; Co-pay program activation and processing.
EVFM shares eked up one cent, or 5%, to 19 cents.
Related Stories
